Drug-induced liver injury secondary to the use of oral contraceptives in a patient with prolonged jaundice and elevated transaminases: Case report
DOI:
https://doi.org/10.59093/27112330.102Keywords:
contraceptive agents, drug-induced liver injury, hepatitis, liver toxicity, jaundice, transaminases.Abstract
Drug-induced liver injury is a rule-out diagnosis. Typically, it occurs in patients who develop clinical and biochemical changes compatible with hepatitis, but related to a history of recent onset of pharmacological agents, and resolves after withdrawal of the noxious substances. Its development has been described with the use of some antibiotics, antituberculosis agents, statins, herbal and nonsteroidal anti inflammatory drugs; however, there are few reports of cases with the use of oral contraceptives, in which the appearance of idiosyncratic mechanisms can lead to the presentation of clinical features such as jaundice and laboratory tests abnormalities, like transaminase elevation, requiring extensive studies to rule out other pathologies that may have this clinical presentation, wich represents a clinical challenge. We present a case report of a patient who had chronic use of implantable contraceptives and who, after adjustment of therapy with the start of oral contraceptives, developed an episode of marked elevation of transaminases and jaundice.
Downloads
References
Andrade RJ, Chalasani N, Björnsson ES, Suzuki A, Kullak-Ublick GA, Watkins PB, et al. Drug-induced liver injury. Nat Rev Dis Primers 2019;5:58. https://doi.org/10.1038/s41572-019-0105-0.
Shehu AI, Ma X, Venkataramanan R. Mechanisms of drug-induced hepatotoxicity. Clin Liver Dis 2017;21:35-54. https://doi.org/10.1016/j.cld.2016.08.002.
Hoofnagle JH, Björnsson ES. Drug-induced liver injury-Types and Phenotypes. N Engl J Med 2019;381:264-273. https://doi.org/10.1056/NEJMra1816149.
García-Cortés M, Robles-Díaz M, Stephens C, Ortega-Alonso A, Lucena MI, Andrade RJ. Drug induced liver injury: an update. Arch Toxicol 2020;94:3381-3407. https://doi.org/10.1007/s00204-020-02885-1.
Qureshi ZP, Seoane-Vázquez E, Rodríguez-Monguio R, Stevenson KB, Szeinbach SL. Market withdrawal of new molecular entities approved in the United States from 1980 to 2009. Pharmacoepidemiol Drug Saf 2011;20:772-777. https://doi.org/10.1002/pds.2155.
Stephens C, Robles-Díaz M, Medina-Cáliz I, García-Cortés M, Ortega-Alonso A, Sanabria-Cabrera J, et al. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. J Hepatol 2021;75:86-97. https://doi.org/10.1016/j.jhep.2021.01.029.
Elouni B, Ben Salem C, Zamy M, Ganne N, Beaugrand M, Bouraoui K, Biour M. Cytolytic hepatitis possibly related to levonorgestrel/ethinylestradiol oral contraceptive use: 2 case reports. Ann Pharmacother 2010;44:2035-2037. https://doi.org/10.1345/aph.1P201.
Stannov SU, Ries A, Bang UC. Hepatotoxicity induced by a second-generation combined oral contraceptive: case report and review of the literature. Eur J Contracept Reprod Health Care 2019;24:322-324. https://doi.org/10.1080/13625187.2019.1602722.
Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR. ACG Clinical Guideline: Diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 2021;116:878-898. https://doi.org/10.14309/ajg.0000000000001259.
Björnsson ES. Clinical management of patients with drug-induced liver injury (DILI). United European Gastroenterol J 2021;9:781-786. https://doi.org/10.1002/ueg2.12113.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol 2019;70:1222-1261. https://doi.org/10.1016/j.jhep.2019.02.014.
de Boer YS, Kosinski AS, Urban TJ, Zhao Z, Long N, Chalasani N, et al. Features of autoimmune hepatitis in patients with drug-induced liver injury. Clin Gastroenterol Hepatol 2017;15:103-112. https://doi.org/10.1016/j.cgh.2016.05.043.
Gondal B, Aronsohn A. A systematic approach to patients with jaundice. Semin Intervent Radiol 2016;33:253-258. https://doi.org/10.1055/s-0036-1592331.
Cano-Paniagua A, Cifuentes-Posada L, Amariles-Muñoz P. Toxicidad hepática causada por medicamentos: revisión estructurada. Rev Col Gastroenterol 2017;32:337-348. https://doi.org/10.22516/25007440.177.
Lahoti S, Lee WM. Hepatotoxicity of anticholesterol, cardiovascular, and endocrine drugs and hormonal agents. Gastroenterol Clin North Am 1995;24:907-922.
Pape S, Schramm C, Gevers TJ. Clinical management of autoimmune hepatitis. United European Gastroenterol J 2019;7:1156-1163. https://doi.org/10.1177/2050640619872408.
Hu PF, Xie WF. Corticosteroid therapy in drug-induced liver injury: pros and cons. J Dig Dis 2019;20:122-126. https://doi.org/10.1111/1751-2980.12697.
Kleiner DE. Drug-induced liver injury: the hepatic pathologist's approach. Gastroenterol Clin North Am 2017 J;46:273-296. https://doi.org/10.1016/j.gtc.2017.01.004.
Hashimoto R, Chang KJ. Endoscopic ultrasound guided hepatic interventions. Dig Endosc 2021;33:54-65. https://doi.org/10.1111/den.13661.
Mohan BP, Shakhatreh M, Garg R, Ponnada S, Adler DG. Efficacy and safety of EUS-guided liver biopsy: a systematic review and meta-analysis. Gastrointest Endosc 2019;89:238-246. https://doi.org/10.1016/j.gie.2018.10.018.
Temple R. Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 2006;15:241-243. https://doi.org/10.1002/pds.1211.
Hayashi PH, Rockey DC, Fontana RJ, Tillmann HL, Kaplowitz N, Barnhart HX, et al. Death and liver transplantation within 2 years of onset of drug-induced liver injury. Hepatology 2017;66:1275-1285. https://doi.org/10.1002/hep.29283.
Björnsson HK, Björnsson ES. Drug-induced liver injury: pathogenesis, epidemiology, clinical features, and practical management. Eur J Intern Med 2022;97:26-31. https://doi.org/10.1016/j.ejim.2021.10.035.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 The authors retain all copyright and grant the Colombian Association of Hepatology a non-exclusive right to publish and disseminate their work.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Hepatología’s authorship policy is based on the criteria established by the International Committee of Medical Journal Editors (ICMJE) to credit a person for their work while assigning them responsibility for its publication.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
